Moderna, Inc. is one of the most recognized pharmaceutical and biotechnology companies in the world for developing a highly effective vaccine against SARS-CoV-2. With its established subsidiaries in Japan, South Korea, and Australia, the company has announced on February 15 its plan to expand its commercial network across Asia with four new subsidiaries including Taiwan, Malaysia, Singapore, and Hong Kong.
“After a decade of pioneering the development of our mRNA platform, we were ready to play a critical role in combating the COVID-19 pandemic globally,” said Stéphane Bancel, CEO of Moderna.
Subsidiaries in APAC Will Continue Support mRNA Vaccines and Medications
Moderna’s new subsidiaries will continue to provide local presence to support the delivery of mRNA vaccines and therapeutics.
Bancel further added, “with the addition of four subsidiaries in Asia, we look forward to new opportunities to leverage our mRNA platform to help solve health challenges, including those with a high burden of disease in the Asia-Pacific region.”
Moderna’s Upcoming Development Programs
After developing the second FDA-approved mRNA vaccine against SARS-CoV-2, Moderna continues to upgrade its COVID-19 strategy to combat COVID variants.
Furthermore, Moderna is also working on mRNA medicines development to prevent and treat diseases with significant unmet needs, including infectious diseases, immuno-oncology, and autoimmune diseases.